目的 探討鼻淵舒口服液聯(lián)合鹽酸羥甲唑啉治療慢性鼻–鼻竇炎的臨床療效。方法 選取2022年3月—2024年4月廣州市第十二人民醫(yī)院收治的鼻炎患者106例，依據(jù)用藥情況分為對(duì)照組（53例）和治療組（53例）。對(duì)照組給予鹽酸羥甲唑啉噴霧劑，一側(cè)1～3噴/次，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服鼻淵舒口服液，10 mL/次，2次/d。兩組患者均用藥7周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時(shí)間，鼻腔鼻竇結(jié)局測試量表評(píng)分（SNOT-20），及血清缺氧誘導(dǎo)因子-1α（HIF-1α）、白細(xì)胞介素-1β（IL-β）、腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，治療組總有效率為96.23%，明顯高于對(duì)照組（83.02%，P＜0.05）。治療后，與對(duì)照組比較，治療組癥狀好轉(zhuǎn)時(shí)間均明顯短于對(duì)照組（P＜0.05）。治療后，治療組SNOT-20評(píng)分明顯低于治療前（P＜0.05），且明顯低于對(duì)照組（P＜0.05）。治療后，兩組患者血清IL-1β、IL-6、TNF-α、HIF-1α水平明顯低于治療前（P＜0.05），且治療后治療組患者血清炎性因子水平明顯低對(duì)照組（P＜0.05）。結(jié)論 鼻淵舒口服液聯(lián)合鹽酸羥甲唑啉治療慢性鼻–鼻竇炎，能改善鼻竇炎患者癥狀，糾正機(jī)體炎癥反應(yīng)狀態(tài)，提高患者生活質(zhì)量。

Objective To explore the clinical efficacy of Biyuanshu Oral Liquid combined with oxymetazoline in treatment of chronic rhinosinusitis. Method Patients (106 cases) with chronic rhinosinusitis in Guangzhou Twelfth People's Hospital from March 2022 to April 2024 were divided into control (53 cases) and treatment (53 cases) group by situation of medication. Patients in the control group were administered with Oxymetazoline Hydrochloride Spray, 1 — 3 sprays/time of one side nose, twice daily. Patients in the treatment group were po administered with Biyuanshu Oral Liquid, 10 mL/time, twice daily. Patients in two groups were treated for 7 weeks. After treatment, the clinical evaluations were evaluated, the symptom relief time, SNOT-20 scores, and the levels of IL-1β, HIF-1α, TNF-α, and IL-6 in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate in the treatment group was 96.23%, which was higher than that in the control group (83.02%, P < 0.05). After treatment, compared with the control group, the time of symptoms improved in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the SNOT-20 score in the treatment group was significantly lower than that before treatment (P < 0.05), and it significantly lower than that in control group after treatment (P < 0.05). After treatment, the levels of serum inflammatory factors IL-1β, IL-6, TNF-α, and HIF-1α in two groups were significantly lower than those before treatment (P < 0.05), and the levels of serum inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Biyuanshu Oral Liquid combined with oxymetazoline in treatment of chronic rhinosinusitis can greatly improve the symptoms of patients with sinusitis, correct the inflammatory response, and improve the quality of life of patients.

R976

廣東省醫(yī)學(xué)科研基金項(xiàng)目(B2024258);廣州市科技計(jì)劃項(xiàng)目(2024A03J0492)